Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts

Area of Science:

• Oncology
• Radiopharmaceutical Therapy
• Nuclear Medicine

Background:

• Prostate specific membrane antigen (PSMA) is a validated target for prostate cancer therapies.
• The FDA approval of 177Lutetium (177Lu)-PSMA-617 marks a significant advancement in treating metastatic castrate-resistant prostate cancer (mCRPC).
• Numerous PSMA-targeted radiopharmaceuticals are under active development.

Purpose of the Study:

• To review the current landscape and future directions of PSMA-targeted radiopharmaceuticals in prostate cancer.
• To highlight the progress of various ligands and isotopes in clinical development.
• To discuss the potential of emerging therapies, including tandem approaches.

Main Methods:

• Review of ongoing and completed clinical trials involving PSMA-targeted agents.
• Analysis of different targeting moieties (monoclonal antibodies, small molecules) and radioisotopes (beta and alpha emitters).
• Evaluation of preliminary data on efficacy and toxicity of investigational agents.

Main Results:

• 177Lu-PSMA-617 is FDA-approved for advanced mCRPC, with 177Lu-PSMA I&T in Phase III trials.
• Development includes antibody-based (e.g., J591, TLX591) and small molecule-based (e.g., PSMA-617, PSMA I&T, MIP-1095) agents.
• Alpha emitters like 225Actinium (225Ac) show promise but require further toxicity data; tandem therapies are being explored.

Conclusions:

• The field of PSMA-targeted radiopharmaceuticals is rapidly evolving with diverse therapeutic options.
• Targeted alpha therapies represent a particularly promising avenue for future development.
• Continued research and clinical trials are essential to optimize PSMA-targeted treatments for prostate cancer.